- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Non-JAK Inhibitor Therapy Options Available for Vitiligo Treatment
Dr King presents interleukin-15, a non-JAK inhibitor therapy option for the treatment of vitiligo.
EP: 1.Illustrating the Presentation of Vitiligo
EP: 2.Prevalence of Vitiligo Across Patient Demographics
EP: 3.Clinical Burden Associated with Vitiligo
EP: 4.Payer Considerations Unique to Vitiligo Treatment
EP: 5.Comorbidities Associated with Vitiligo
EP: 6.Frontline Therapies for Vitiligo Treatment
EP: 7.Economic Burden Surrounding Vitiligo
EP: 8.Vitiligo Diagnosis Determining Treatment Pathways
EP: 9.Optimal Therapies for Treating Vitiligo
EP: 10.Aligning Payer and Provider Considerations
EP: 11.Unmet Needs in Vitiligo Treatment Landscape
EP: 12.Role of JAK Inhibitors in Treatment of Vitiligo
EP: 13.Safety Considerations for Vitiligo-Focused Drug Therapies
EP: 14.Non-JAK Inhibitor Therapy Options Available for Vitiligo Treatment
EP: 15.Payer Support for Emerging Vitiligo Treatments
EP: 16.Trajectory of Vitiligo Treatment Landscape
Jeffrey D. Dunn, PharmD, MBA: There’s at least 1 interleukin in development, a non-JAK inhibitor. Dr King, do you want to take that one?
Brett King, MD, PhD: Sure. There’s a clinical trial happening at the Immune Tolerance Network, a part of the NIH [National Institutes of Health], of an antibody to interleukin-15, or IL-15. IL-15 is thought to be an important mediator of T-cell survival in the skin in patients with vitiligo. The whole idea being that often when we stop treatment, the disease and white spots come back. Not uncommonly, they come back in the same spots where they were to begin with.
Why is that? There’s a lot of good science that says there’s a certain set of immune cells that reside in those patches of vitiligo and that their survival relies on interleukin-15, or IL-15. The whole concept behind this trial is if you give an IL-15 antibody, then you dampen that signal or you take away the survival signal, and maybe we’re able to remit. We’re getting close conceptually to remitting—not curing—disease without ongoing treatment. It’s a provocative concept, and we’re a long way away, but it’s interesting because I suspect the payers would love if we were saying that somebody is going to undergo treatment for their psoriasis and it’s going to go away for 5 years.
Jeffrey D. Dunn, PharmD, MBA: Drug holidays, yes.
Brett King, MD, PhD: That would be huge, but we aren’t there. I don’t think we’re even close in psoriasis, but we’re having that conversation in vitiligo, which is exciting, but a ways away.
Transcript edited for clarity.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
May 16th 2025This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
